Prescription attached:-

đŠē LIPU MED â Full Clinical Prescription Review & Working Diagnostic Assessment
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϏāĻĒāĻžāĻāĻā§āĻž āĻŦāĻž āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ (Suspected Scabies), āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ (Onychomycosis)āĨ¤ āĻā§āϞāĻāĻžāύāĻŋāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš (Pruritic Dermatitis) āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĒā§āϰā§āĻŖ āĻŦāĻŋāĻŦāϰāĻŖ āĻ āĻĒāϰā§āĻā§āώāĻžāϰ āϰāĻŋāĻĒā§āϰā§āĻ āύāĻž āĻĨāĻžāĻāĻžā§ āĻāĻā§āϞ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āύā§āĨ¤
Clinical Status: Provisional Working Assessment â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§āĨ¤
Prescription date: 02 October 2026
Review date: Wednesday, 21 October 2026
Source: One prescription photograph; no separate laboratory report or clinical skin photograph.
Overall diagnostic confidence: 0.70/1.00
â ī¸ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Clinical Safety Alert: āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Cefixime 400 mg āĻĻāĻŋāύ⧠āĻĻā§āĻŦāĻžāϰ, Ivermectin 12 mg āĻāĻ āĻĻāĻŋāύ āĻĒāϰāĻĒāϰ āĻĒāĻžāĻāĻāĻāĻŋ āĻĄā§āĻ āĻāĻŦāĻ Permethrin 5% āĻĒāĻžāĻāĻ āϰāĻžāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤ āϏāĻžāϧāĻžāϰāĻŖ uncomplicated scabies-āĻāϰ āĻĒā§āϰāĻāϞāĻŋāϤ guideline regimen āĻĨā§āĻā§ āĻāĻā§āϞ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĻāĻžāĻŦā§ āĻāĻŋāύā§āύāĨ¤ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āĻĄā§āĻ āĻ āϰā§āĻā§āϰ āϤā§āĻŦā§āϰāϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤ āϰā§āĻā§āĻā§ āĻĒāϰā§āĻā§āώāĻž āύāĻž āĻāϰ⧠āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻ āύā§āϏāϰāĻŖ āĻŦāĻž āĻĒāϰāĻŋāĻŦāϰā§āϤāύā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻĻā§āĻā§āĻž āύāĻŋāϰāĻžāĻĒāĻĻ āύā§āĨ¤
đĻ SECTION 01 â Website-Verified Case Identification / āĻā§ā§āĻŦāϏāĻžāĻāĻ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻā§āϏ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ
1.1 Website Verification / āĻā§ā§āĻŦāϏāĻžāĻāĻ āϝāĻžāĻāĻžāĻ
āĻāĻ raiyyantahsan.com-āĻāϰ Medical Blog āĻāĻŦāĻ Dermatology archive āϝāĻžāĻāĻžāĻ āĻāϰ⧠āĻĒāĻžāĻā§āĻž āϤāĻĨā§āϝ:
| Verification parameter | Latest published | Proposed new case |
|---|---|---|
| Total Case (TC) | TC (1408) | TC (1409) |
| Department Code (DCS) | 02 | 02 |
| Dermatology Case No. | 101 | 102 |
| Department | Dermatology | Dermatology |
| Disease | Suspected Scabies | Suspected Scabies with Possible Onychomycosis |
āĻā§ā§āĻŦāϏāĻžāĻāĻā§āϰ āϏāϰā§āĻŦāĻļā§āώ āĻĻā§āĻļā§āϝāĻŽāĻžāύ Medical Blog post āĻāĻŋāϞ TC(1408), Oncology Case No. 36, āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ 20 October 2026āĨ¤ Dermatology archive-āĻ āϏāϰā§āĻŦāĻļā§āώ āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻā§āϏ āĻāĻŋāϞ TC(1392).(02).Dermatology Department Case No (101)āĨ¤ āϤāĻžāĻ āύāϤā§āύ āĻā§āϏā§āϰ āĻāύā§āϝ TC(1409), DCS(02), Dermatology Case No (102) āĻĒā§āϰāϏā§āϤāĻžāĻŦ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤ āĻāĻāĻŋ āĻāĻāύ⧠āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻā§āϏ āύāĻŽā§āĻŦāϰ āύā§; āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āύāϤā§āύ āĻĒā§āϏā§āĻ āĻāϏā§āĻā§ āĻāĻŋ āύāĻž āĻĒā§āύāϰāĻžā§ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Website numbering confidence: 0.96
1.2 Patient Identification / āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ
| Parameter | Prescription findings |
|---|---|
| Patient name / āύāĻžāĻŽ | āĻšāĻžāϤ⧠āϞā§āĻāĻž; āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻĒāĻžāĻ ā§āĻĻā§āϧāĻžāϰ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| Age / āĻŦā§āϏ | 28 years / ā§¨ā§Ž āĻŦāĻāϰ |
| Sex / āϞāĻŋāĻā§āĻ | Not documented / āĻāϞā§āϞā§āĻ āύā§āĻ |
| Registration No. | 8663 |
| Visit No. | 1 |
| Prescription date | 02/10/2026 |
| Physician | āĻĄāĻž. āϧā§āĻŽāĻžāύ āĻĻā§āĻŦāύāĻžāĻĨ |
| Department | Dermatology / āĻāϰā§āĻŽāϰā§āĻ āĻŦāĻŋāĻāĻžāĻ |
| Weight / āĻāĻāύ | Not documented / āĻāϞā§āϞā§āĻ āύā§āĻ |
| Blood pressure | Not documented |
| Allergy status | Not documented |
| Pregnancy/lactation status | Not documented |
Extraction confidence: 0.98; unreadable patient name: 0.30
đĻ SECTION 02 â Original Prescription: Complete Clinical Extraction / āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āϤāĻĨā§āϝ
2.1 C/C â Chief Complaint / āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
Prescription findings: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ C/C āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻāĨ¤
āϤāĻŦā§ āĻāώā§āϧ āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻĨā§āĻā§ āĻāĻŋāĻāĻŋā§āϏāĻ āĻā§ā§āĻāĻāĻŋ āϏāĻŽāϏā§āϝāĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰā§āĻā§āύ āĻŦāϞ⧠āĻŦā§āĻāĻž āϝāĻžā§āĨ¤
| Possible clinical complaint | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Evidence status | Confidence |
|---|---|---|---|
| Pruritus | āϤā§āĻŦāĻā§ āĻā§āϞāĻāĻžāύāĻŋ | Atrizin-āĻāϰ āύāĻŋāϰā§āĻĻā§āĻļā§ āĻā§āϞāĻāĻžāύāĻŋāϰ āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§ | 0.95 |
| Scabies-like skin eruption | āĻā§āϏāĻĒāĻžāĻāĻā§āĻžāϰ āĻŽāϤ⧠āĻāϰā§āĻŽāϰā§āĻ | Permethrin āĻ Ivermectin prescribed | 0.82 |
| Nail discoloration or dystrophy | āύāĻā§āϰ āϰāĻ āĻ āĻāĻ āύā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | Nail serum, Clotrimazole āĻ Terbinafine prescribed | 0.70 |
| Possible alopecia/hair concern | āĻā§āϞ āĻĒā§āĻž āĻŦāĻž āĻā§āϞā§āϰ āϏāĻŽāϏā§āϝāĻž | Hair serum prescribed | 0.55 |
| Secondary bacterial infection | āϤā§āĻŦāĻā§ āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒāϰā§āϝāĻžā§ā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ | Antibiotic prescribed; āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āϞā§āĻāĻž āύā§āĻ | 0.45 |
Important: āĻāĻā§āϞ⧠āĻāώā§āϧ āĻĨā§āĻā§ āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻŽāϏā§āϝāĻž; āϰā§āĻā§āϰ āϏāϰāĻžāϏāϰāĻŋ āĻŦāϰā§āĻŖāĻŋāϤ C/C āĻšāĻŋāϏā§āĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
2.2 O/E â On Examination / āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžā§ āĻĒā§āϰāĻžāĻĒā§āϤ āϤāĻĨā§āϝ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠O/E āĻļāĻŋāϰā§āύāĻžāĻŽ āϰā§ā§āĻā§, āĻāĻŋāύā§āϤ⧠āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ examination finding āϞā§āĻāĻž āύā§āĻāĨ¤
Not documented:
- Skin lesion morphology â āϤā§āĻŦāĻā§āϰ āĻā§āώāϤā§āϰ āĻāĻā§āϤāĻŋ āĻ āϧāϰāύāĨ¤
- Burrows â āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻŽāĻžāĻāĻā§āϰ āϤā§āϰāĻŋ āϏāϰ⧠āϏā§āĻĄāĻŧāĻā§āĻā§āϰ āĻŽāϤ⧠āĻĻāĻžāĻāĨ¤
- Papules â āĻā§āĻ āĻāĻāĻā§ āĻĢā§āϏāĻā§ā§āĻŋāĨ¤
- Excoriations â āĻā§āϞāĻāĻžāύā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻāĻā§ā§āϰ āĻā§āώāϤāĨ¤
- Pustules â āĻĒā§āĻāĻāϝā§āĻā§āϤ āĻĢā§āϏāĻā§ā§āĻŋāĨ¤
- Nail examination â āύāĻā§āϰ āĻĒāϰā§āĻā§āώāĻžāĨ¤
- Scalp examination â āĻŽāĻžāĻĨāĻžāϰ āϤā§āĻŦāĻ āĻĒāϰā§āĻā§āώāĻžāĨ¤
Confidence: 0.99
2.3 Doctor’s Diagnosis â Dx / āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ Dx āĻ āĻāĻļā§ āĻĻā§āĻāĻŋ āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āϞā§āĻāĻž āĻĻā§āĻļā§āϝāĻŽāĻžāύ:
- âISâ
- âOnyâ â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒāĻžāĻ ā§āĻĻā§āϧāĻžāϰ
āĻāĻāĻžāύ⧠âISâ āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āϰā§āĻĒāĻāĻŋāϰ āĻĒā§āϰā§āĻŖ āĻ āϰā§āĻĨ āϞā§āĻāĻž āύā§āĻāĨ¤ āϤāĻžāĻ āĻāĻāĻŋāĻā§ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ Infected Scabies āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
āĻĻā§āĻŦāĻŋāϤā§ā§ āĻšāĻžāϤ⧠āϞā§āĻāĻž āĻļāĻŦā§āĻĻāĻāĻŋ âOnyâ āĻšāϤ⧠āĻĒāĻžāϰā§, āϝāĻž āĻāĻŋāĻāĻŋā§āϏāĻ Onychomycosis āĻŦā§āĻāĻžāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰ⧠āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤ āϤāĻŦā§ āĻšāĻžāϤā§āϰ āϞā§āĻāĻžāϰ āĻāĻžāϰāĻŖā§ āĻāĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Documented diagnosis confidence:
- âISâ āϞā§āĻāĻž āĻāĻā§: 0.95
- âISâ = Infected Scabies: 0.35
- âOnyâ = Onychomycosis: 0.65
2.4 Investigation / āĻĒāϰā§āĻā§āώāĻž
No investigation was prescribed or documented.
āĻ āϰā§āĻĨāĻžā§ āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠CBC, KOH examination, nail microscopy, fungal culture āĻŦāĻž LFT āĻā§āύā§āĻāĻŋāϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻĻā§āĻāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Confidence: 0.99
2.5 Treatment Plan / āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώā§āϝ:
- Scabicidal treatment â āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āĻŽāĻžāĻāĻ āĻĻā§āϰ āĻāϰāĻžāĨ¤
- Antipruritic treatment â āĻā§āϞāĻāĻžāύāĻŋ āĻāĻŽāĻžāύā§āĨ¤
- Antifungal treatment â āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
- Anti-inflammatory treatment â āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āĨ¤
- Possible bacterial infection treatment â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
- Nail and hair supportive care â āύāĻ āĻ āĻā§āϞā§āϰ āϝāϤā§āύāĨ¤
Treatment-intent confidence: 0.88
đĻ SECTION 03 â Patient History Assessment / āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻŽā§āϞā§āϝāĻžā§āύ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŖ history āϞā§āĻāĻž āύā§āĻāĨ¤
| History parameter | English meaning | Prescription findings |
|---|---|---|
| I/H | Immunization History â āĻāĻŋāĻāĻžāĻĻāĻžāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| O/H | Obstetric History â āĻāϰā§āĻāϧāĻžāϰāĻŖ āĻ āĻĒā§āϰāϏāĻŦā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| D/H | Drug History â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāώā§āϧā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| M/H | Medical History â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| Surgical History | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ āĻĒāĻžāϰā§āĻļāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| Family History | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| Allergy History | āĻāώā§āϧ āĻŦāĻž āĻ āύā§āϝ āĻāĻŋāĻā§āϤ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāϤāĻŋāĻšāĻžāϏ | N/A |
| O/S/E | On Systemic Examination â āĻŦāĻŋāĻāĻŋāύā§āύ āĻ āĻā§āĻāϤāύā§āϤā§āϰ āĻĒāϰā§āĻā§āώāĻž | N/A |
| O/G/E | On General Examination â āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | N/A |
āĻāĻāĻžāύ⧠N/A = Not Available / āϤāĻĨā§āϝ āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤ āĻāϰ āĻ āϰā§āĻĨ āϰā§āĻā§āϰ āĻā§āύ⧠āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϰā§āĻ āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āύā§āĻâāĻāĻŽāύ āύā§āĨ¤
Confidence: 0.99
Additional History Required / āĻāϰāĻ āϝ⧠āĻāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧠āĻšāĻŦā§
Scabies evaluation-āĻāϰ āĻāύā§āϝ: āϰāĻžāϤ⧠āĻā§āϞāĻāĻžāύāĻŋ āĻŦāĻžā§ā§ āĻāĻŋ āύāĻž, āĻāĻāĻ āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āĻ āύā§āϝāĻĻā§āϰ āĻā§āϞāĻāĻžāύāĻŋ āĻāĻā§ āĻāĻŋ āύāĻž, āĻāĻā§āϞā§āϰ āĻĢāĻžāĻāĻ, āĻāĻŦāĻāĻŋ, āĻā§āĻŽāϰ, āύāĻžāĻāĻŋāϰ āĻāĻžāϰāĻĒāĻžāĻļ āĻŦāĻž āϝā§āύāĻžāĻā§āĻā§ āĻĢā§āϏāĻā§ā§āĻŋ āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
Onychomycosis evaluation-āĻāϰ āĻāύā§āϝ: āύāĻ āĻŽā§āĻāĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž, āĻšāϞā§āĻĻ āĻŦāĻž āϏāĻžāĻĻāĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž, āύāĻ āĻā§āĻā§ āϝāĻžā§ āĻāĻŋ āύāĻž, āĻāĻāĻžāϧāĻŋāĻ āύāĻ āĻāĻā§āϰāĻžāύā§āϤ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻāĻā§ āĻā§āύ⧠antifungal āĻā§āϰāĻšāĻŖ āĻāϰā§āĻā§āύ āĻāĻŋ āύāĻž āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
Drug safety-āĻāϰ āĻāύā§āϝ: Liver disease, kidney disease, diabetes, previous drug allergy, pregnancy possibility āĻāĻŦāĻ āĻāϞāĻŽāĻžāύ āϏāĻŦ āĻāώā§āϧā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.97
đĻ SECTION 04 â Physical Examination / āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
āĻāĻ āĻ āĻāĻļā§ āĻā§āύ⧠findings āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āύā§āĻāĨ¤ āύāĻŋāĻā§āϰ examination-āĻā§āϞ⧠āύāϤā§āύ āĻāϰ⧠āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
| Examination | What to look for / āĻā§ āĻĻā§āĻāϤ⧠āĻšāĻŦā§ |
|---|---|
| General examination | Temperature, pulse, BP, hydration |
| Skin examination | Papules, burrows, excoriations, crusts |
| Interdigital spaces | āĻāĻā§āϞā§āϰ āĻĢāĻžāĻāĻā§ āĻā§āώā§āĻĻā§āϰ āϏā§āĻĄāĻŧāĻā§āĻ āĻŦāĻž āĻĢā§āϏāĻā§ā§āĻŋ |
| Wrist and waist examination | āĻāĻŦāĻāĻŋ āĻ āĻā§āĻŽāϰ⧠āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āϏāĻžāϧāĻžāϰāĻŖ āĻā§āώāϤ |
| Nail examination | Thickening, discoloration, onycholysis |
| Scalp examination | Scaling, inflammation, hair thinning |
| Secondary infection assessment | Pus, warmth, tenderness, spreading redness |
Burrow / āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āϏā§āĻĄāĻŧāĻā§āĻ: āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰ āϏāϰ⧠āĻāĻāĻāĻžāĻŦāĻžāĻāĻāĻž āϰā§āĻāĻž, āϝāĻž āϏā§āϤā§āϰ⧠āĻŽāĻžāĻāĻ āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰā§āϰ āϏā§āϤāϰ⧠āĻ āĻŦāϏā§āĻĨāĻžāύ āĻāϰāĻžāϰ āϏāĻŽā§ āϤā§āϰāĻŋ āĻāϰā§āĨ¤
Onycholysis / āύāĻ āĻāϞāĻāĻž āĻšā§ā§ āϝāĻžāĻā§āĻž: Nail plate āϤāĻžāϰ āύāĻŋāĻā§āϰ nail bed āĻĨā§āĻā§ āĻāϞāĻžāĻĻāĻž āĻšā§ā§ āϝāĻžāĻā§āĻžāĨ¤
Confidence: 0.97
đĻ SECTION 05 â Doctor’s Diagnosis & Clinical Impression / āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϧāĻžāϰāĻŖāĻž
đĸ Suspected Scabies / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϏāĻĒāĻžāĻāĻā§āĻž
Supporting evidence:
- Perosa 5% contains Permethrin, a scabicidal agent.
- Alice 12 mg contains Ivermectin, also used to treat scabies.
- Atrizin prescribed for itching.
āĻāĻ āϤāĻŋāύāĻāĻŋ āĻāώā§āϧā§āϰ āϏāĻŽāύā§āĻŦā§ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤ āϤāĻŦā§ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āĻĻā§āĻļā§āϝāĻŽāĻžāύ burrow, characteristic rash āĻŦāĻž āĻāĻā§āϰāĻžāύā§āϤ āĻŦā§āϝāĻā§āϤāĻŋāϰ āϏāĻāϏā§āĻĒāϰā§āĻļā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Confidence that the physician intended scabies treatment: 0.90
Confidence that the patient truly has scabies: 0.70
đ Possible Onychomycosis / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ
Supporting evidence:
- Fungiben 250 â Terbinafine.
- Clarizol solution â Clotrimazole.
- Nailcis serum â nail-care product.
- Possible handwritten âOnyâ.
āĻāĻ āĻāώā§āϧāĻā§āϞ⧠āύāĻā§āϰ fungal infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻŦāĻž supportive care-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.72
đ Possible Secondary Dermatitis / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻāĻžāύāĻŋāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš
Cetirizine āĻāĻŦāĻ Methylprednisolone āĻĻā§āĻā§āĻžāϰ āĻāĻžāϰāĻŖā§ āĻā§āϞāĻāĻžāύāĻŋ āĻ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.62
đ Possible Secondary Bacterial Infection / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒāϰā§āϝāĻžā§ā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ
Cefixime āĻ Gentamicin-containing cream āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§ā§āĻā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻĒā§āĻāĻ, āĻā§āĻŦāϰ, spreading erythema āĻŦāĻž cellulitis-āĻāϰ āĻā§āύ⧠āĻŦāϰā§āĻŖāύāĻž āύā§āĻāĨ¤
Confidence: 0.45
đĻ SECTION 06 â Investigations / āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž-āύāĻŋāϰā§āĻā§āώāĻž
6.1 Doctor-Advised Investigations / āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āĻĒāϰā§āĻā§āώāĻž
None documented / āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻž āϞā§āĻāĻž āύā§āĻāĨ¤
6.2 My Recommended Investigations / āĻāĻŽāĻžāϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āĻĒāϰā§āĻā§āώāĻž
| Investigation | Purpose / āĻā§āύ āĻĒā§āϰā§ā§āĻāύ | Priority |
|---|---|---|
| Skin examination with dermoscopy | Scabies burrow āĻ mite āĻļāύāĻžāĻā§āϤ | High |
| Skin scraping microscopy | āĻŽāĻžāĻāĻ, āĻĄāĻŋāĻŽ āĻŦāĻž āĻŽāϞā§āϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ āĻļāύāĻžāĻā§āϤ | When indicated |
| Nail clipping for KOH microscopy | āύāĻā§ fungal elements āĻļāύāĻžāĻā§āϤ | High before systemic antifungal |
| Nail fungal culture or PAS histology | Fungal diagnosis confirmation | When indicated |
| ALT, AST, bilirubin | Oral terbinafine-āĻāϰ āĻāĻā§ liver assessment | High |
| CBC | āĻŦā§āϝāĻžāĻĒāĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻŦāĻŋāĻļā§āώ clinical concern āĻĨāĻžāĻāϞ⧠| Conditional |
| Renal function | āĻŦāĻŋāĻļā§āώ āĻā§āĻāĻāĻŋ āĻŦāĻž āĻāώā§āϧā§āϰ āĻĄā§āĻ āϏāĻŽāύā§āĻŦā§ā§āϰ āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠| Conditional |
| Bacterial culture | āĻĒā§āĻāĻāϝā§āĻā§āϤ, recurrent āĻŦāĻž treatment-resistant infection āĻšāϞ⧠| Conditional |
Clinical interpretation: Scabies āϏāĻžāϧāĻžāϰāĻŖāϤ history, examination āĻ dermoscopy āĻĻāĻŋā§ā§ āύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āϝāĻžā§āĨ¤ Negative skin scraping āĻĻāĻŋā§ā§ āϏāĻŦāϏāĻŽā§ scabies āĻŦāĻžāĻĻ āĻĻā§āĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤ Onychomycosis-āĻāϰ āĻā§āώā§āϤā§āϰ⧠systemic antifungal āĻļā§āϰ⧠āĻāϰāĻžāϰ āĻāĻā§ fungal confirmation āĻŦāĻŋāĻļā§āώ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.97
đŠ SECTION 07 â Prescribed Drug Analysis â MedEx āĻ āύā§āϝāĻžā§ā§ / āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāώā§āϧā§āϰ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻŽā§āĻ ā§§ā§§āĻāĻŋ āĻāώā§āϧ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāϏāĻžāĻŽāĻā§āϰ⧠āϰā§ā§āĻā§āĨ¤ MedEx-āĻ āĻĒāĻžāĻā§āĻž drug information āĻāĻŦāĻ āϝā§āϏāĻŦ āĻĒāĻŖā§āϝ MedEx-āĻ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋ, āϏā§āĻā§āϞā§āϰ āĻĒā§āĻĨāĻ āϤāĻĨā§āϝ āύāĻŋāĻā§ āĻĻā§āĻā§āĻž āĻšāϞā§āĨ¤
7.1 Complete Prescribed Medicine Table / āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻāώā§āϧā§āϰ āϤāĻžāϞāĻŋāĻāĻž
| No. | Brand | Generic / Composition | Prescription instruction | Duration |
|---|---|---|---|---|
| 1 | Cefim-3 400 | Cefixime 400 mg | 1+0+1 | 7 days |
| 2 | Atrizin 10 | Cetirizine 10 mg | 0+0+1; itching worse āĻšāϞ⧠| 1 month |
| 3 | Prickly Heat Soap | Medicated cooling soap | Daily bathing | 1 month |
| 4 | Alice 12 | Ivermectin 12 mg | 1 tablet every alternate day | 5 tablets |
| 5 | Solupred 8 | Methylprednisolone 8 mg | 1+0+1 | 5 days |
| 6 | Combiderm Cream | Betamethasone + Clotrimazole + Gentamicin | Twice daily on affected areas if sores | 1 month |
| 7 | Clarizol Solution | Clotrimazole 1% | Morning and evening on affected nails | Continue |
| 8 | Nailcis Serum | Nail repair serum | Every night on affected nails | Continue |
| 9 | Fungiben 250 | Terbinafine 250 mg | 0+0+1 | 2 months |
| 10 | Reona Hair Serum | Hair-care serum | Scalp massage at night | 2 months |
| 11 | Perosa 5% Cream | Permethrin 5% | Whole-body application on specified nights | 2 months printed; 5 applications specified |
Medicine 01 â Cefim-3 400
- Generic name: Cefixime Trihydrate â āϏā§āĻĢāĻŋāĻā§āϏāĻŋāĻŽāĨ¤
- Brand name: Prescription: Cefim-3 400; MedEx-āĻ matching capsule listed as Cefim-3 DS 400.
- MedEx alternate brands: Cef-3 DS, Cefimax, CefiximāĨ¤
- MedEx Therapeutic Class: Third generation cephalosporins â āϤā§āϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ āϏā§āĻĢāĻžāϞā§āϏā§āĻĒā§āϰāĻŋāύāĨ¤
- Pharmacological Class: β-lactam antibiotic â āĻŦāĻŋāĻāĻž-āϞā§āϝāĻžāĻāĻāĻžāĻŽ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
- Use of purpose: Susceptible bacterial infections â āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
- Why prescribed in this patient: Secondary bacterial infection āϏāύā§āĻĻā§āĻšā§ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§; āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύā§āĻāĨ¤
- Side effects: Diarrhoea, abdominal pain, nausea, rash, allergy; rarely severe antibiotic-associated colitisāĨ¤
- MedEx link: Cefim-3 DS 400 mg â MedEx
- Unit and strip price: Capsule ā§ŗ60; 7-capsule strip ā§ŗ420āĨ¤ Other forms: 200 mg capsule, 400 mg tablet, suspension and pediatric dropsāĨ¤
- Mechanism: Bacterial cell-wall synthesis inhibition â āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻā§āώāĻĒā§āϰāĻžāĻā§āϰ āϤā§āϰāĻŋ āĻŦāύā§āϧ āĻāϰā§āĨ¤
- Indications: Selected respiratory, urinary and other susceptible bacterial infectionsāĨ¤
- Interactions + contraindications: Cephalosporin allergy; warfarin āĻŦāĻž anticoagulant-āĻāϰ āϏāĻā§āĻā§ bleeding risk āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύ; renal impairment-āĻ dose adjustment āϞāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Precautions: āĻ āϝāĻĨāĻž antibiotic āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠resistance āĻ adverse effects āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
- Dosage: āϏāĻžāϧāĻžāϰāĻŖ adult dosage 200â400 mg/day, infection āĻ āύā§āϝāĻžā§ā§ āĻāĻāĻŦāĻžāϰ āĻŦāĻž āĻĻā§āĻ āĻāĻžāĻā§āĨ¤ Prescription-āĻāϰ 400 mg twice daily = 800 mg/day, āϝāĻž āϏāĻžāϧāĻžāϰāĻŖ recommended daily dose-āĻāϰ āĻĻā§āĻŦāĻŋāĻā§āĻŖāĨ¤ āĻāϰā§āϰāĻŋ dose verification āĻĒā§āϰā§ā§āĻāύāĨ¤
- Pregnancy & lactation: āĻĒā§āϰā§ā§āĻāύ āĻāĻžā§āĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āύā§; prescriber-āĻāϰ individual riskâbenefit assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug identification confidence: 0.98; patient-specific indication: 0.45.
Medicine 02 â Atrizin 10 mg
- Generic name: Cetirizine Hydrochloride â āϏā§āĻāĻŋāϰāĻŋāĻāĻŋāύāĨ¤
- Brand name: Atrizin 10, BeximcoāĨ¤
- Alternate brands: Arcet, Alatrol āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Cetirizine brandsāĨ¤
- MedEx Therapeutic Class: Anti-histamine â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
- Pharmacological Class: Second-generation H1 receptor antagonistāĨ¤
- Purpose: Itching, urticaria and allergic symptoms āĻāĻŽāĻžāύā§āĨ¤
- Why prescribed: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻā§āϞāĻāĻžāύāĻŋ āĻŦā§āĻļāĻŋ āĻšāϞ⧠āϏā§āĻŦāύā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤ Scabies-associated itch āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Side effects: Drowsiness, dry mouth, fatigue, headacheāĨ¤
- MedEx link: Atrizin 10 mg â MedEx
- Price: ā§ŗ3/tablet; 15-tablet strip ā§ŗ45āĨ¤ Other compositions: 5 mg/5 ml syrup āĻāĻŦāĻ 2.5 mg/ml dropsāĨ¤
- Mechanism: Histamine H1 receptor blockade â āĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύā§āϰ āĻĒā§āϰāĻāĻžāĻŦ āĻāĻŽāĻžā§āĨ¤
- Indications: Allergic rhinitis, urticaria āĻ allergic pruritusāĨ¤
- Interactions + contraindications: Cetirizine allergy; alcohol āĻ sedating medicines-āĻāϰ āϏāĻā§āĻā§ āĻā§āĻŽāĻāĻžāĻŦ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
- Precautions: Renal impairment-āĻ dose adjustment āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Dosage: Adult standard dose 10 mg once daily; prescribed āϰāĻžāϤ⧠āĻāĻāĻāĻŋāĨ¤
- Pregnancy & lactation: Pregnancy-āϤ⧠āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž; breast milk-āĻ āϝāĻžā§, āϤāĻžāĻ lactation-āĻ āϏāϤāϰā§āĻāϤāĻžāĨ¤
Confidence: 0.98
Medicine 03 â Prickly Heat Soap
- Generic name: Medicated cooling soap; āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ pharmaceutical generic āύā§āĻāĨ¤
- Brand: Prickly Heat SoapāĨ¤
- MedEx alternate brand: Not verified â MedEx-āĻ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ listing āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
- Therapeutic Class: MedEx therapeutic class unavailableāĨ¤
- Pharmacological Class: Skin cleanser/cooling preparationāĨ¤
- Purpose: āϤā§āĻŦāĻ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāĻž, prickling āĻŦāĻž itching sensation āĻāĻŽāĻžāύā§āĨ¤
- Why prescribed: āĻā§āϞāĻāĻžāύāĻŋāϝā§āĻā§āϤ āϤā§āĻŦāĻā§ supportive hygiene-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝā§āĨ¤
- Side effects: Skin dryness, irritation, contact dermatitisāĨ¤
- MedEx link: Not available; Prickly Heat Soap product information
- Price: āĻāĻāĻāĻŋ 75 g product listing-āĻ āĻĒā§āϰāĻžā§ ā§ŗ732 MRP āĻĻā§āĻāĻž āϝāĻžā§; retailer āĻ āύā§āϝāĻžā§ā§ āĻĻāĻžāĻŽ āĻāĻŋāύā§āύāĨ¤
- Mechanism: Cleansing āĻāĻŦāĻ menthol/camphor-āĻāĻžāϤā§ā§ āĻāĻĒāĻžāĻĻāĻžāύā§āϰ cooling sensationāĨ¤ Exact formula product label āĻ āύā§āϝāĻžā§ā§ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
- Indications: Prickly heat āĻ itching-āĻāϰ supportive relief; āĻāĻāĻŋ scabies mite eradication treatment āύā§āĨ¤
- Interactions + contraindications: Fragrance āĻŦāĻž āĻāĻĒāĻžāĻĻāĻžāύāĻāύāĻŋāϤ sensitivity āĻĨāĻžāĻāϞ⧠āĻā§āĻŋā§ā§ āĻāϞāĻžāĨ¤
- Precautions: āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϏā§āĻāύā§āϧāĻŋ āĻŦāĻž irritating soap dermatitis āĻŦāĻžā§āĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Dosage: Prescription āĻ āύā§āϝāĻžā§ā§ āĻĻā§āύāĻŋāĻ āĻā§āϏāϞāĨ¤
- Pregnancy & lactation: Exact formulation āĻ āύā§āϝāĻžā§ā§ safety āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤
Confidence: 0.80; exact product formulation: 0.65.
Medicine 04 â Alice 12 mg
- Generic name: Ivermectin â āĻāĻāĻāĻžāϰāĻŽā§āĻāĻāĻŋāύāĨ¤
- Brand: Alice 12, Square PharmaceuticalsāĨ¤
- MedEx alternate brands: A-Mectin, AvemecāĨ¤
- MedEx Therapeutic Class: Anthelmintic â āĻĒāϰāĻā§āĻŦā§āύāĻžāĻļāĻāĨ¤
- Pharmacological Class: Avermectin antiparasiticāĨ¤
- Purpose: Scabies mite āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāϰāĻā§āĻŦā§ āĻĻā§āϰ āĻāϰāĻžāĨ¤
- Why prescribed: āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āϏāĻŦāĻā§ā§ā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝāĨ¤
- Side effects: Nausea, dizziness, diarrhoea, rash; rare neurological reactionsāĨ¤
- MedEx link: Alice 12 mg â MedEx
- Price: ā§ŗ20/tablet; 10-tablet strip ā§ŗ200āĨ¤ Other composition: 6 mg tabletāĨ¤
- Mechanism: Parasite glutamate-gated chloride channels-āĻ āĻāĻžāĻ āĻāϰ⧠paralysis āĻāĻāĻžā§āĨ¤
- Indications: Scabies, strongyloidiasis, onchocerciasis, selected parasitic infestationsāĨ¤
- Interactions + contraindications: Hypersensitivity; anticoagulants āĻ āĻ āύā§āϝāĻžāύā§āϝ interacting medicines review āĻĒā§āϰā§ā§āĻāύāĨ¤
- Precautions: āĻļāϰā§āϰā§āϰ āĻāĻāύ āύāĻž āĻā§āύ⧠fixed dose āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
- Dosage: CDC āĻ āύā§āϝāĻžā§ā§ classic scabies-āĻ 200 micrograms/kg per dose, āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĄā§āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ 7â14 āĻĻāĻŋāύ āĻĒāϰā§āĨ¤ āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠12 mg āĻāĻ āĻĻāĻŋāύ āĻĒāϰāĻĒāϰ āĻŽā§āĻ āĻĒāĻžāĻāĻāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ āϞā§āĻāĻž āĻāĻā§āĨ¤ āĻāĻāĻŋ routine classic scabies regimen āύā§āĨ¤ Severe āĻŦāĻž crusted scabies-āĻ āĻāĻŋāύā§āύ multiple-dose regimen āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āϤāĻžāϰ āĻā§āύ⧠clinical evidence āĻāĻāĻžāύ⧠āύā§āĻāĨ¤
- Pregnancy & lactation: Pregnancy-āϤ⧠safety established āύā§; breastfeeding-āĻ clinical evaluation āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug confidence: 0.99; appropriateness of prescribed schedule: uncertain, requires review.
Medicine 05 â Solupred 8 mg
- Generic: Methylprednisolone â āĻŽāĻŋāĻĨāĻžāĻāϞāĻĒā§āϰā§āĻĄāύāĻŋāϏā§āϞā§āύāĨ¤
- Brand: Solupred 8, ZiskaāĨ¤
- Alternate brands: Depomed, MedrolāĨ¤
- MedEx Therapeutic Class: Glucocorticoids â āĻā§āϞā§āĻā§āĻāϰā§āĻāĻŋāĻā§ā§āĻĄāĨ¤
- Pharmacological Class: Systemic corticosteroidāĨ¤
- Purpose: Inflammation āĻāĻŦāĻ immune-mediated symptoms āĻāĻŽāĻžāύā§āĨ¤
- Why prescribed: āϤā§āĻŦā§āϰ inflammatory itching āĻŦāĻž dermatitis āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Side effects: Gastric irritation, increased blood glucose, sleep disturbance, mood changes, infection susceptibilityāĨ¤
- MedEx link: Solupred 8 mg â MedEx
- Price: ā§ŗ9.50/tablet; 10-tablet strip ā§ŗ95āĨ¤ Other strengths: 2, 4, 16 mgāĨ¤
- Mechanism: Glucocorticoid receptor activation āĻāĻŦāĻ inflammatory gene signalling modulationāĨ¤
- Indications: Selected inflammatory, allergic, autoimmune and other steroid-responsive disordersāĨ¤
- Interactions + contraindications: Active untreated systemic fungal infection, serious infection-related concerns; NSAIDs āĻ antidiabetic medicines-āĻāϰ āϏāĻā§āĻā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ interaction āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Precautions: Systemic steroid uncomplicated scabies-āĻāϰ routine treatment āύā§āĨ¤ Infection masking, worsening fungal disease āĻāĻŦāĻ immunosuppression-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻā§āĨ¤
- Dosage: Prescription: 8 mg twice daily for five daysāĨ¤ āĻāĻāĻŋ āϰā§āĻāύāĻŋāϰā§āĻĻāĻŋāώā§āĻ clinical assessment āĻāĻžā§āĻž āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋ āύāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
- Pregnancy & lactation: Individual riskâbenefit assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug confidence: 0.99; indication confidence: 0.55.
Medicine 06 â Combiderm Cream
- Generic: Betamethasone + Clotrimazole + GentamicināĨ¤
- Brand: CombidermāĨ¤
- Alternate brands: Aristoderm, Bet-CG, Betson-CG, TrioskināĨ¤
- MedEx Therapeutic Class: Betamethasone & Combined preparationsāĨ¤
- Pharmacological Class: Corticosteroid + Azole antifungal + Aminoglycoside antibioticāĨ¤
- Purpose: Selected inflammatory dermatoses with bacterial or fungal complicationsāĨ¤
- Why prescribed: āϤā§āĻŦāĻā§ āĻā§āώāϤ āĻŦāĻž secondary infection-āĻāϰ āϏāύā§āĻĻā§āĻšā§āĨ¤
- Side effects: Burning, irritation, skin thinning, hypopigmentation; prolonged steroid use-āĻ skin atrophyāĨ¤
- MedEx link: Combiderm composition and MedEx brands
- Price: 15 g tube ā§ŗ75āĨ¤ Composition: Betamethasone 0.05% + Clotrimazole 1% + Gentamicin 0.1%āĨ¤
- Mechanism: Betamethasone inflammation āĻāĻŽāĻžā§; Clotrimazole fungal ergosterol synthesis āĻŦāĻžāϧāĻž āĻĻā§ā§; Gentamicin bacterial protein synthesis āĻŦāĻžāϧāĻž āĻĻā§ā§āĨ¤
- Indications: Selected steroid-responsive infected dermatosesāĨ¤
- Interactions + contraindications: Component hypersensitivity; other corticosteroid products-āĻāϰ āϏāĻā§āĻā§ combined exposure āĻŦāĻžā§ā§āĨ¤
- Precautions: āĻāĻ āĻŽāĻžāϏ āϧāϰ⧠steroid-combination cream āĻŦā§āϝāĻŦāĻšāĻžāϰ skin atrophy āĻ tinea incognito-āĻāϰ āĻā§āĻāĻāĻŋ āϤā§āϰāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻŽā§āĻ, skin folds āĻāĻŦāĻ genital area-āϤ⧠āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻžāĨ¤
- Dosage: Prescription: affected area-āϤ⧠twice daily, āĻāĻ āĻŽāĻžāϏāĨ¤ Duration āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
- Pregnancy & lactation: Extensive āĻŦāĻž prolonged application āĻā§āĻžāύā§; breastfeeding-āĻāϰ āĻāĻā§ clinical evaluationāĨ¤
Confidence: 0.97
Medicine 07 â Clarizol Solution
- Generic: Clotrimazole 1% â āĻā§āϞā§āĻā§āϰāĻŋāĻŽāĻžāĻāϞāĨ¤
- Brand: Clarizol, InceptaāĨ¤
- Alternate brands: Dermasim topical solution, Trimazole solutionāĨ¤
- MedEx Therapeutic Class: Drugs for subcutaneous and mycoses; Topical Antifungal preparationsāĨ¤
- Pharmacological Class: Imidazole antifungalāĨ¤
- Purpose: Superficial fungal infectionāĨ¤
- Why prescribed: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻā§āϰ fungal infection āĻŦāĻž nail-fold fungal involvement-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāύā§āϝāĨ¤
- Side effects: Local burning, redness, irritationāĨ¤
- MedEx link: Clarizol 1% Solution â MedEx
- Price: 20 ml bottle ā§ŗ68āĨ¤ Also available as 1% creamāĨ¤
- Mechanism: Fungal ergosterol synthesis inhibitionāĨ¤
- Indications: Dermatophytosis, candidiasis, fungal skin infection; periungual fungal infection-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Interactions + contraindications: Clotrimazole hypersensitivity; topical interaction evidence āϏā§āĻŽāĻŋāϤāĨ¤
- Precautions: āϏāĻžāϧāĻžāϰāĻŖ clotrimazole solution nail plate-āĻāϰ āĻā§āϤāϰ⧠āϝāĻĨā§āώā§āĻ penetration āύāĻžāĻ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤ Confirmed extensive onychomycosis-āĻāϰ āĻāύā§āϝ āĻāĻāĻŋ āĻāĻāĻāĻāĻžāĻŦā§ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĨ¤
- Dosage: Prescription: affected nails-āĻ āϏāĻāĻžāϞ⧠āĻ āĻŦāĻŋāĻā§āϞ⧠āĻĒā§āϰā§ā§āĻ, continueāĨ¤
- Pregnancy & lactation: āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āϏā§āĻŽāĻŋāϤ topical use āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤
Confidence: 0.98
Medicine 08 â Nailcis Serum
- Generic: No established single pharmaceutical genericāĨ¤
- Brand: CISDERMA Nailcis Nail Repair SerumāĨ¤
- MedEx alternate brand: Not verifiedāĨ¤
- MedEx Therapeutic Class: Not listed/verifiedāĨ¤
- Pharmacological Class: Cosmetic/cosmeceutical nail-care preparationāĨ¤
- Purpose: Nail discoloration, brittleness āĻ nail-care supportāĨ¤
- Why prescribed: āύāĻā§āϰ āĻāĻ āύ āĻ āϰāĻ āĻāύā§āύāϤ āĻāϰāĻžāϰ supportive treatment āĻšāĻŋāϏā§āĻŦā§āĨ¤
- Side effects: Possible contact irritation or allergyāĨ¤
- MedEx link: No verified MedEx listingāĨ¤ Manufacturer/product information
- Price: 15 ml product retailer listing approximately ā§ŗ1,280; āĻ āύā§āϝ retailer-āĻ MRP ā§ŗ1,380āĨ¤
- Mechanism: Product-specific ingredients āĻ āύā§āϝāĻžā§ā§ nail hydration, exfoliation āĻŦāĻž conditioningāĨ¤ Manufacturing and retailer ingredient lists differ; exact label āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
- Indications: Cosmetic nail repair support; clinically proven stand-alone antifungal cure āύā§āĨ¤
- Interactions + contraindications: Ingredient hypersensitivity; damaged nail āĻŦāĻž surrounding skin-āĻ irritation āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Precautions: Confirmed onychomycosis-āĻāϰ evidence-based antifungal therapy-āĻāϰ āĻŦāĻŋāĻāϞā§āĻĒ āύā§āĨ¤
- Dosage: Prescription āĻ āύā§āϝāĻžā§ā§ āϰāĻžāϤ⧠affected nails-āĻ āĻĒā§āϰā§ā§āĻāĨ¤
- Pregnancy & lactation: Exact formulation āĻāĻžāύāĻž āĻāĻžā§āĻž āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ safety conclusion āĻĻā§āĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤
Product identity confidence: 0.90; formulation confidence: 0.55.
Medicine 09 â Fungiben 250 mg
- Generic: Terbinafine Hydrochloride â āĻāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύāĨ¤
- Brand: Fungiben 250, Derma PharmaceuticalsāĨ¤
- Alternate brands: Mycocure, Mycofin, MycofreeāĨ¤
- MedEx Therapeutic Class: Other Antifungal preparations, Topical Antifungal preparations â MedEx monograph-āĻāϰ listed classificationāĨ¤
- Pharmacological Class: Allylamine antifungalāĨ¤
- Purpose: Dermatophyte fungal infection eradicationāĨ¤
- Why prescribed: āϏāĻŽā§āĻāĻžāĻŦā§āϝ onychomycosis-āĻāϰ systemic treatmentāĨ¤
- Side effects: Gastrointestinal upset, taste disturbance, rash, abnormal liver enzymes; rarely serious liver injuryāĨ¤
- MedEx link: Fungiben 250 mg â MedEx
- Price: ā§ŗ60/tablet; 10-tablet strip ā§ŗ600āĨ¤ Other form: Terbinafine 1% creamāĨ¤
- Mechanism: Fungal squalene epoxidase inhibitionāĨ¤
- Indications: Dermatophyte onychomycosis āĻāĻŦāĻ selected skin fungal infectionsāĨ¤
- Interactions + contraindications: Active/chronic liver disease; CYP2D6-metabolized medicines, including selected antidepressants and beta-blockers, require interaction reviewāĨ¤
- Precautions: Oral terbinafine āĻļā§āϰ⧠āĻāϰāĻžāϰ āĻāĻā§ baseline ALT/AST āĻāĻŦāĻ liver disease assessment āĻĒā§āϰā§ā§āĻāύāĨ¤ Dark urine, jaundice āĻŦāĻž persistent nausea āĻšāϞ⧠urgent medical reviewāĨ¤
- Dosage: Adult onychomycosis: 250 mg once daily, typically 6 weeks for fingernails āĻāĻŦāĻ 12 weeks for toenailsāĨ¤ Prescription-āĻ āĻĻā§āĻ āĻŽāĻžāϏ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§; āĻā§āύ āύāĻ āĻāĻā§āϰāĻžāύā§āϤ āϤāĻž āĻāĻžāύāĻž āύāĻž āĻĨāĻžāĻāĻžā§ duration-āĻāϰ āϝāĻĨāĻžāϰā§āĻĨāϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
- Pregnancy & lactation: Pregnancy-āϤ⧠initiation generally postponed; oral terbinafine breastfeeding-āĻ recommended āύā§āĨ¤
Drug confidence: 0.99; indication confidence: 0.78.
Medicine 10 â Reona Hair Serum
- Generic: No established pharmaceutical genericāĨ¤
- Brand: Reona Hair SerumāĨ¤
- MedEx alternate brand: Not verifiedāĨ¤
- MedEx Therapeutic Class: Not availableāĨ¤
- Pharmacological Class: Hair-care/cosmetic preparationāĨ¤
- Purpose: Hair conditioning, scalp-care supportāĨ¤
- Why prescribed: āĻā§āϞā§āϰ āĻā§āύ⧠āϏāĻŽāϏā§āϝāĻžāϰ supportive care-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§; hair-loss diagnosis āϞā§āĻāĻž āύā§āĻāĨ¤
- Side effects: Possible irritation, contact allergyāĨ¤
- MedEx link: No verified MedEx listingāĨ¤ Reona Hair Serum product information
- Price: āĻāĻāĻāĻŋ 100 ml retailer listing-āĻ āĻĒā§āϰāĻžā§ ā§ŗ2,375āĨ¤ Product variant āĻ seller āĻ āύā§āϝāĻžā§ā§ āĻĻāĻžāĻŽ āĻāĻŋāύā§āύāĨ¤
- Mechanism: Exact formulation verified āύā§; cosmetic conditioning effect expectedāĨ¤
- Indications: Hair dryness or cosmetic hair-care concern; androgenetic alopecia-āĻāϰ established treatment āύā§āĨ¤
- Interactions + contraindications: Ingredient sensitivity; topical scalp products-āĻāϰ āϏāĻā§āĻā§ irritation āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
- Precautions: āĻā§āϞ āĻĒā§āĻžāϰ āĻāĻžāϰāĻŖ āύāĻŋāϰā§āĻŖā§ āĻāĻžā§āĻž āĻāĻāĻŋ disease-specific therapy āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
- Dosage: Prescription: āϰāĻžāϤ⧠scalp-āĻ massage āĻāϰ⧠āĻĒā§āϰā§ā§āĻ, āĻĻā§āĻ āĻŽāĻžāϏāĨ¤
- Pregnancy & lactation: Exact ingredients āϝāĻžāĻāĻžāĻ āύāĻž āĻāϰ⧠safety āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.80; specific formulation confidence: 0.50.
Medicine 11 â Perosa 5% Cream
- Generic: Permethrin 5% â āĻĒāĻžāϰāĻŽā§āĻĨā§āϰāĻŋāύāĨ¤
- Brand: Perosa, Eskayef PharmaceuticalsāĨ¤
- Alternate brands: Scabex, Permin, Permisol, PerscabāĨ¤
- MedEx Therapeutic Class: Parasiticidal preparationsāĨ¤
- Pharmacological Class: Synthetic pyrethroid scabicideāĨ¤
- Purpose: Scabies mites eradicationāĨ¤
- Why prescribed: āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠scabies treatment-āĻāϰ āϏāĻŦāĻā§ā§ā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāώā§āϧāĨ¤
- Side effects: Burning, stinging, itching, erythemaāĨ¤
- MedEx link: Perosa 5% Cream â MedEx
- Price: 30 g tube ā§ŗ55āĨ¤
- Mechanism: Mite neuronal sodium channels-āĻāϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻŦā§āϝāĻžāĻšāϤ āĻāϰ⧠paralysis āĻāĻŦāĻ death āĻāĻāĻžā§āĨ¤
- Indications: Scabies āĻāĻŦāĻ selected ectoparasitic infestationsāĨ¤
- Interactions + contraindications: Pyrethroid āĻŦāĻž formulation component hypersensitivityāĨ¤
- Precautions: āĻā§āĻ, āĻŽā§āĻā§āϰ āĻā§āϤāϰ āĻ mucosal surfaces āĻā§āĻžāϤ⧠āĻšāĻŦā§; excessive applications skin irritation āĻŦāĻžā§āĻžā§āĨ¤
- Dosage: Prescription-āĻ āϰāĻžāϤ⧠neck-to-toes application āĻāĻŦāĻ ā§§āĻŽ, ⧍ā§, ā§āĻŽ, ā§§ā§ĒāϤāĻŽ āĻ ā§¨ā§§āϤāĻŽ āϰāĻžāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤ āϏāĻžāϧāĻžāϰāĻŖ classic scabies-āĻ guideline āĻ āύā§āϝāĻžā§ā§ āĻāĻāĻāĻŋ application, āĻĒā§āϰā§ā§āĻāύ⧠āĻĒā§āϰāĻžā§ 7 āĻĻāĻŋāύ āĻĒāϰ⧠āĻĻā§āĻŦāĻŋāϤā§ā§ application; 8â14 āĻāĻŖā§āĻāĻž āĻĒāϰ⧠āϧā§ā§ā§ āĻĢā§āϞāϤ⧠āĻšā§āĨ¤ āĻĒāĻžāĻāĻāĻŦāĻžāϰ application routine regimen āύā§; severe āĻŦāĻž crusted scabies āĻĨāĻžāĻāϞ⧠āĻāϞāĻžāĻĻāĻž specialist protocol āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Pregnancy & lactation: Pregnancy-āϤ⧠topical permethrin āϏāĻžāϧāĻžāϰāĻŖāϤ preferred scabies treatments-āĻāϰ āĻāĻāĻāĻŋ, āϤāĻŦā§ individual clinical assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.99
𩷠SECTION 08 â Bangladesh Clinical Practice: MedEx-Based Drug Options / āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ āϤāĻžāϞāĻŋāĻāĻž
āύāĻŋāĻā§āϰ āĻāώā§āϧāĻā§āϞ⧠āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§āϰ āĻŦāĻžāĻāĻžāϰ⧠MedEx-listed optionsāĨ¤ āĻāĻā§āϞ⧠āϏāĻŦ āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϤāĻžāϞāĻŋāĻāĻž āύā§āĨ¤
| No. | Clinical purpose | Generic | Bangladesh brand examples | Clinical rationale |
|---|---|---|---|---|
| 1 | Classic scabies | Permethrin 5% | Perosa, Scabex, Permin | āĻŽāĻžāĻāĻ āύāĻŋāϰā§āĻŽā§āϞ |
| 2 | Selected scabies cases | Ivermectin | Alice, A-Mectin, Avemec | Systemic antiparasitic |
| 3 | Symptomatic itching | Cetirizine | Atrizin, Arcet | āĻā§āϞāĻāĻžāύāĻŋāϰ āĻāĻĒāĻļāĻŽ |
| 4 | Confirmed onychomycosis | Terbinafine | Fungiben, Mycocure, Mycofin | Nail dermatophytes āύāĻŋāϰā§āĻŽā§āϞ |
| 5 | Selected superficial fungal infection | Clotrimazole 1% | Clarizol, Dermasim | Topical antifungal |
| 6 | Confirmed susceptible bacterial infection | Cefixime | Cefim-3 DS, Cef-3 DS | āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ bacterial infection; routine scabies therapy āύ⧠|
| 7 | Selected inflammatory dermatosis | Methylprednisolone | Solupred, Depomed | Steroid-responsive inflammation; routine scabies therapy āύ⧠|
| 8 | Selected infected inflammatory dermatosis | Betamethasone + Clotrimazole + Gentamicin | Combiderm, Bet-CG | āĻā§āĻŦāϞ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ indication-āĻ; indiscriminate use āύ⧠|
āĻāĻ āĻŦāĻŋāĻāϞā§āĻĒāĻā§āϞ⧠MedEx-āĻāϰ generic āĻ brand listings āĻĨā§āĻā§ āύā§āĻā§āĻžāĨ¤ Scabies āĻŦāĻž nail fungus-āĻāϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§, disease severity, contraindication āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ investigation āĻ āύā§āϝāĻžā§ā§ medication āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.96
đ¨ SECTION 09 â My Clinical Working Assessment / āĻāĻŽāĻžāϰ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§
đĒ 9.1 Prescription-Ready Provisional Diagnosis / āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻžāϰ āĻāĻĒāϝā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Recommended diagnostic note:
Dx: Suspected Scabies (B86), with possible associated Pruritic Dermatitis; R/O Onychomycosis (B35.1). Secondary bacterial infection not established.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻŦāĻž āĻā§āϏāĻĒāĻžāĻāĻā§āĻž, āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻāĻžāύāĻŋāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš; āύāĻā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒāϰā§āϝāĻžā§ā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Confidence: Scabies 0.70 | Onychomycosis 0.72 | Secondary dermatitis 0.62
đĒ 9.2 Specific Specialist Referral / āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻāĻžāĻā§ āϰā§āĻĢāĻžāϰ
Primary referral: Dermatologist / āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Referral note: Suspected scabies with possible nail dermatophytosis; evaluate need for systemic antifungal, confirm diagnosis and review non-standard multidrug regimenāĨ¤
āĻ āϰā§āĻĨāĻžā§ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻ āύāĻā§āϰ fungal infection āĻāĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰā§, systemic antifungal āĻĒā§āϰā§ā§āĻāύ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāώā§āϧā§āϰ āĻĄā§āĻ āĻ duration āύāĻŋāϰāĻžāĻĒāĻĻ āĻāĻŋ āύāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Referral confidence: 0.99
đ§ 9.3 Clinical Diagnostic Conclusion / āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻāĻĒāϏāĻāĻšāĻžāϰ
Most likely treatment target: Scabies.
Probable concurrent condition: Onychomycosis.
Unconfirmed conditions: Bacterial skin infection, alopecia disorder, severe inflammatory dermatitis.
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻāĻ āϏāĻā§āĻā§ scabicidal, antifungal, antihistamine, steroid āĻāĻŦāĻ antibiotic therapy āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§āĨ¤ āĻāϰ āĻĢāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻāĻžāϧāĻŋāĻ āĻāϰā§āĻŽāϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰāĻā§āύ āĻŦāϞ⧠āϧāĻžāϰāĻŖāĻž āĻšā§, āĻāĻŋāύā§āϤ⧠āĻĒā§āϰāϤāĻŋāĻāĻŋ āϰā§āĻā§āϰ objective evidence āĻĒāĻžāĻā§āĻž āϝāĻžā§ āύāĻžāĨ¤
Overall diagnostic confidence: 0.70
9.4 Doctor’s Dx vs My Dx â Clinical Comparison
| Comparison | Doctor’s documented Dx | My assessment | Agreement |
|---|---|---|---|
| Scabies | âISâ; meaning unclear | Suspected scabies | đĸ Treatment pattern supports |
| Onychomycosis | Possible âOnyâ | Possible onychomycosis | đĸ Probable |
| Pruritic dermatitis | Not explicitly documented | Possible | đ Inferred |
| Secondary bacterial infection | Not explicitly documented | Not confirmed | đ Insufficient evidence |
| Hair disorder | Not documented | Undetermined | đ No diagnosis possible |
đĸ Similarity / āĻŽāĻŋāϞ
Doctor’s medication selection āĻāĻŦāĻ āĻāĻŽāĻžāϰ working assessmentâāĻāĻā§ā§āĻ scabies āĻāĻŦāĻ possible nail fungal infection-āĻāϰ āĻĻāĻŋāĻā§ āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰāĻā§āĨ¤
đ Dissimilarity / āĻ āĻŽāĻŋāϞ
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŦā§āϝāĻŦāĻšā§āϤ âISâ abbreviation-āĻāϰ āĻ āϰā§āĻĨ āϏā§āĻĒāώā§āĻ āύā§āĨ¤ āϤāĻžāĻ physician-confirmed scabies diagnosis āĻĻāĻžāĻŦāĻŋ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤ āĻāĻāĻžā§āĻž āĻāĻŋāĻā§ medication regimen routine guideline-based treatment āĻĨā§āĻā§ āĻāĻŋāύā§āύ; āĻāĻā§āϞ⧠āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
Comparison confidence: 0.82 for treatment intent; 0.60 for actual disease concordance.
đĻ SECTION 10 â Disease Definition / āϰā§āĻā§āϰ āϏāĻāĻā§āĻāĻž
10.1 Scabies / āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻā§?
Definition: Scabies is a contagious parasitic skin infestation caused by Sarcoptes scabiei var. hominis.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻšāϞ⧠Sarcoptes scabiei āύāĻžāĻŽā§āϰ āĻ āϤāĻŋāĻā§āώā§āĻĻā§āϰ āĻĒāϰāĻā§āĻŦā§ āĻŽāĻžāĻāĻ āĻĻā§āĻŦāĻžāϰāĻž āϏā§āώā§āĻ āϏāĻāĻā§āϰāĻžāĻŽāĻ āĻāϰā§āĻŽāϰā§āĻāĨ¤
āĻāĻ āĻŽāĻžāĻāĻ āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰāĻŋāĻāĻžāĻā§ āϏā§āĻĄāĻŧāĻā§āĻ āϤā§āϰāĻŋ āĻāϰ⧠āĻāĻŦāĻ immune reaction-āĻāϰ āĻāĻžāϰāĻŖā§ āϤā§āĻŦā§āϰ āĻā§āϞāĻāĻžāύāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
10.2 Onychomycosis / āύāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻā§?
Definition: Onychomycosis is a fungal infection involving the nail plate, nail bed or nail matrixāĨ¤
āĻŦāĻžāĻāϞāĻž: āύāĻā§āϰ āĻĒā§āϞā§āĻ, āύāĻŋāĻā§āϰ āĻ āĻāĻļ āĻŦāĻž āύāĻ āϤā§āϰāĻŋāϰ āĻ āĻāĻļā§ āĻāϤā§āϰāĻžāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĻā§ Onychomycosis āĻŦāϞā§āĨ¤
āύāĻ āĻŽā§āĻāĻž āĻšāĻā§āĻž, āĻāĻā§āĻā§āϰ āĻšāĻā§āĻž, āĻšāϞā§āĻĻ āĻŦāĻž āϏāĻžāĻĻāĻž āϰāĻ āϧāĻžāϰāĻŖ āĻāϰāĻž āĻāĻŦāĻ nail plate āĻāϞāĻāĻž āĻšā§ā§ āϝāĻžāĻā§āĻž āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āĻļāĻŋāώā§āĻā§āϝāĨ¤
Confidence: 0.99
đĻ SECTION 11 â Etiology & Pathophysiology / āϰā§āĻā§āϰ āĻāĻžāϰāĻŖ āĻ āϰā§āĻāϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
Scabies
Etiology / āĻāĻžāϰāĻŖ: Sarcoptes scabiei var. hominis miteāĨ¤
Pathophysiology / āϰā§āĻāϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž: āĻŽāĻžāĻāĻ āϤā§āĻŦāĻā§āϰ stratum corneum āϏā§āϤāϰ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰā§āĨ¤ Mite antigen, eggs āĻ faecal material-āĻāϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠delayed hypersensitivity reaction āϤā§āϰāĻŋ āĻšā§āĨ¤ āĻĢāϞ⧠pruritus, papules āĻ inflammatory skin lesions āĻĻā§āĻāĻž āĻĻāĻŋāϤ⧠āĻĒāĻžāϰā§āĨ¤
Onychomycosis
Etiology / āĻāĻžāϰāĻŖ: Dermatophytes, āĻŦāĻŋāĻļā§āώ āĻāϰ⧠Trichophyton rubrum; āĻāĻāĻžā§āĻž yeasts āĻ āĻāĻŋāĻā§ non-dermatophyte mouldsāĨ¤
Pathophysiology: Fungal organisms nail keratin-āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āϏā§āώā§āĻāĻŋ āĻāϰā§āĨ¤ āĻĢāϞ⧠nail discoloration, thickening, subungual debris āĻāĻŦāĻ onycholysis āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.97
đĻ SECTION 12 â Clinical Features / āϰā§āĻā§āϰ āϞāĻā§āώāĻŖāϏāĻŽā§āĻš
| Disease | Clinical feature | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ |
|---|---|---|
| Scabies | Nocturnal pruritus | āϰāĻžāϤ⧠āĻā§āϞāĻāĻžāύāĻŋ āĻŦā§āĻļāĻŋ |
| Scabies | Papular eruption | āĻā§āĻ āĻāĻāĻā§ āĻĢā§āϏāĻā§ā§āĻŋ |
| Scabies | Burrows | āϤā§āĻŦāĻā§ āϏāϰ⧠āϏā§āĻĄāĻŧāĻā§āĻā§āϰ āĻŽāϤ⧠āĻĻāĻžāĻ |
| Scabies | Interdigital involvement | āĻāĻā§āϞā§āϰ āĻĢāĻžāĻāĻā§ āĻā§āώāϤ |
| Scabies | Household clustering | āĻāĻāĻ āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āĻāĻāĻžāϧāĻŋāĻ āĻŦā§āϝāĻā§āϤāĻŋāϰ āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻā§āĻž |
| Onychomycosis | Nail thickening | āύāĻ āĻŽā§āĻāĻž āĻšāĻā§āĻž |
| Onychomycosis | Nail discoloration | āύāĻā§āϰ āϰāĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
| Onychomycosis | Subungual hyperkeratosis | āύāĻā§āϰ āύāĻŋāĻā§ āĻā§āϰāĻžāĻāĻŋāύ āĻāĻŽāĻž |
| Onychomycosis | Onycholysis | āύāĻā§āϰ āĻĒā§āϞā§āĻ āĻāϞāĻāĻž āĻšā§ā§ āϝāĻžāĻā§āĻž |
Important: āĻāĻ āϞāĻā§āώāĻŖāĻā§āϞā§āϰ āĻ āϧāĻŋāĻāĻžāĻāĻļāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠documented āύā§; āĻāĻā§āϞ⧠āϰā§āĻ āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āϏāĻŽā§ āĻā§āĻāĻāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98
đĻ SECTION 13 â Differential Diagnosis / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻāύāĻŋāϰā§āĻŖā§
| Differential diagnosis | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Distinguishing findings |
|---|---|---|
| Scabies | āĻā§āϏāĻĒāĻžāĻāĻā§āĻž | Night itching, burrows, affected contacts |
| Atopic dermatitis | āĻ ā§āϝāĻžāĻā§āĻĒāĻŋāĻ āĻāĻāĻāĻŋāĻŽāĻž | Chronic relapsing eczema, typical distribution |
| Allergic contact dermatitis | āϏāĻāϏā§āĻĒāϰā§āĻļāĻāύāĻŋāϤ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āĻĒā§āϰāĻĻāĻžāĻš | Relevant exposure and distribution |
| Tinea corporis | āĻļāϰā§āϰā§āϰ āĻĻāĻžāĻĻ | Annular scaly plaques |
| Papular urticaria | āĻĒā§āĻāĻžāĻŽāĻžāĻā§ā§āϰ āĻāĻžāĻŽā§ā§ āĻĢā§āϏāĻā§ā§āĻŋ | Exposure-related grouped papules |
| Onychomycosis | āύāĻā§ āĻāϤā§āϰāĻžāĻ | Mycological evidence |
| Nail psoriasis | āύāĻā§āϰ āϏā§āϰāĻŋā§āĻžāϏāĻŋāϏ | Pitting, oil spots, onycholysis |
Most important differential question: āĻā§āϞāĻāĻžāύāĻŋ āĻ skin lesions-āĻāϰ āĻĒā§āϰāĻā§āϤ pattern āĻāĻŋ classic scabies-āĻāϰ āϏāĻā§āĻā§ āĻŽā§āϞā§, āύāĻžāĻāĻŋ eczema āĻŦāĻž fungal dermatitis-āĻāϰ āϏāĻā§āĻā§?
Confidence: 0.94
đĻ SECTION 14 â Investigation Interpretation / āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻāĻ āĻā§āϏ⧠āĻā§āύ⧠laboratory report āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤ āϤāĻžāĻ āύāĻŋāĻā§āϰ āĻ āĻāĻļāĻāĻŋ proposed interpretation framework, āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϤ āĻĢāϞāĻžāĻĢāϞ āύā§āĨ¤
| Test | Possible result | Clinical interpretation |
|---|---|---|
| Skin scraping microscopy | Mite, eggs or faecal pellets found | Scabies diagnosis supported |
| Dermoscopy | Characteristic mite/burrow sign | Scabies strongly supported |
| Nail KOH | Fungal hyphae found | Nail fungal infection supported |
| Nail culture/PAS | Fungal elements or organism identified | Onychomycosis diagnosis strengthened |
| ALT/AST | Elevated | Terbinafine safety assessment required |
| Bilirubin | Elevated | Hepatic assessment required |
Clinical limitation: Nail discoloration alone cannot distinguish fungal infection from psoriasis, trauma or other nail disorders. Similarly, treatment with Permethrin does not establish a positive scabies test.
Confidence: 0.98
đĻ SECTION 15 â Management & Treatment â Guideline-Based Approach / āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž
15.1 Scabies Management / āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž
CDC āĻ āύā§āϝāĻžā§ā§ classic scabies-āĻāϰ standard treatments-āĻāϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§:
Permethrin 5% cream: Adult patient-āĻ āĻāϞāĻž āĻĨā§āĻā§ āĻĒāĻžā§ā§āϰ āĻāĻā§āϞ āĻĒāϰā§āϝāύā§āϤ āϤā§āĻŦāĻā§ āĻĒā§āϰā§ā§āĻ, 8â14 āĻāĻŖā§āĻāĻž āĻĒāϰ⧠āϧā§ā§ā§ āĻĢā§āϞāĻž; āĻĒā§āϰā§ā§āĻāύ⧠āĻĒā§āϰāĻžā§ āĻāĻ āϏāĻĒā§āϤāĻžāĻš āĻĒāϰ⧠āĻĻā§āĻŦāĻŋāϤā§ā§ applicationāĨ¤
Ivermectin: 200 micrograms/kg per dose, āϏāĻžāϧāĻžāϰāĻŖāϤ 7â14 āĻĻāĻŋāύā§āϰ āĻŦā§āϝāĻŦāϧāĻžāύ⧠āĻĻā§āĻ āĻĄā§āĻāĨ¤ āĻāĻāύāĻāĻŋāϤā§āϤāĻŋāĻ āĻĄā§āĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
Contact management: āĻāĻāĻ household-āĻāϰ close contacts-āĻĻā§āϰ āĻāĻāϏāĻā§āĻā§ evaluation/treatment; āĻŦā§āϝāĻŦāĻšā§āϤ āĻāĻžāĻĒā§, āĻŦāĻŋāĻāĻžāύāĻžāϰ āĻāĻžāĻĻāϰ āĻ āϤā§ā§āĻžāϞ⧠hot washing/drying; āϧā§ā§āĻž āϝāĻžā§ āύāĻž āĻāĻŽāύ āĻāĻŋāύāĻŋāϏ āĻā§ā§āĻ āĻĻāĻŋāύ āϏāĻŋāϞ āĻāϰāĻžāĨ¤
Post-scabetic itch: āϏāĻĢāϞ treatment-āĻāϰ āĻĒāϰāĻ āĻā§ā§āĻ āϏāĻĒā§āϤāĻžāĻš āĻā§āϞāĻāĻžāύāĻŋ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻļā§āϧ⧠residual itching-āĻāϰ āĻāĻžāϰāĻŖā§ āĻŦāĻžāϰāĻŦāĻžāϰ scabicide āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĒāϝā§āĻā§āϤ āύā§āĨ¤
15.2 Onychomycosis Management / āύāĻā§āϰ āĻāϤā§āϰāĻžāĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž
Confirm fungal infection: Nail clipping, KOH, PAS āĻŦāĻž cultureāĨ¤
Assess liver function: Oral terbinafine-āĻāϰ āĻāĻā§ liver disease history āĻ baseline transaminasesāĨ¤
Systemic antifungal: Confirmed dermatophyte nail infection-āĻ Terbinafine 250 mg/day āϏāĻžāϧāĻžāϰāĻŖāϤ fingernail-āĻāϰ āĻāύā§āϝ 6 weeks, toenail-āĻāϰ āĻāύā§āϝ 12 weeksāĨ¤
Follow-up: Clinical response āύāĻā§āϰ āύāϤā§āύ āĻŦā§āĻĻā§āϧāĻŋ āĻ āύā§āϝāĻžā§ā§ āϧā§āϰ⧠āĻĻā§āĻāĻž āϝāĻžā§āĨ¤ āĻĒā§āϰā§ā§āĻāύ⧠liver-function monitoringāĨ¤
Confidence: 0.97
15.3 Critical Review of This Prescription / āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϤā§āϰā§āĻāĻŋ āĻŦāĻž āϝāĻžāĻāĻžāĻā§ā§āϰ āĻŦāĻŋāώā§
| Concern | Clinical significance | Recommended response |
|---|---|---|
| Cefixime 800 mg/day | Above usual adult daily dose | Verify prescription and indication |
| Ivermectin 12 mg alternate-day Ã5 | Non-standard for uncomplicated scabies | Check body weight, diagnosis and severity |
| Permethrin on 5 nights | More intensive than routine treatment | Exclude crusted scabies; confirm schedule |
| Methylprednisolone | Not routine scabies treatment | Reassess steroid indication |
| Combiderm for 1 month | Prolonged steroid-combination exposure | Review duration and application sites |
| Terbinafine for 2 months | Requires fungal confirmation and liver assessment | Check nail site, KOH/PAS, ALT/AST |
| Nailcis/Reona | Adjunctive cosmetic products | Do not assume proven disease-modifying efficacy |
Safety review confidence: 0.98
đĻ SECTION 16 â Clinical Prescription Demo, Overview & Actionable Plan / āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύāĻŽā§āύāĻž, āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ āĻ āĻāϰāĻŖā§ā§
16.1 Clinical Prescription Demo / āύāĻŽā§āύāĻž āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ
Educational documentation example only â āĻāĻāĻŋ āύāϤā§āύ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻĻā§āĻļ āύā§āĨ¤
Patient: 28 years
Date: 21/10/2026
Department: Dermatology
C/C: Not documented in source prescription; clarify pruritus, rash distribution, duration and nail symptomsāĨ¤
O/E: Pending clinical examinationāĨ¤
Provisional Dx:
1. Suspected Scabies â B86
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻŦāĻž āĻā§āϏāĻĒāĻžāĻāĻā§āĻžāĨ¤
2. R/O Onychomycosis â B35.1
āύāĻā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
3. Possible Pruritic Dermatitis
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻāĻžāύāĻŋāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
Investigations:
- Dermatological examination Âą dermoscopyāĨ¤
- Nail KOH microscopy Âą fungal culture/PASāĨ¤
- ALT/AST before oral terbinafineāĨ¤
- Additional investigations according to examinationāĨ¤
Rx review: Original medications reconciled; do not reproduce potentially inappropriate dosing without direct prescriber confirmationāĨ¤
Advice: Household contact evaluation, skin hygiene, avoid unnecessary steroid use, return for medication safety reviewāĨ¤
Follow-up: Dermatology review promptly, particularly before continuing oral antibiotic, multiple-dose ivermectin or systemic antifungal treatmentāĨ¤
16.2 Overview / āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
Most likely clinical interpretation: āĻāĻŋāĻāĻŋā§āϏāĻ āϏā§āĻā§āϝāĻžāĻŦāĻŋāϏ āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ nail fungal disease-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰāϤ⧠āĻā§ā§ā§āĻā§āύāĨ¤
What remains unconfirmed: āϰā§āĻā§āϰ actual lesions, fungal diagnosis, secondary bacterial infection āĻ hair-loss disorderāĨ¤
Highest-priority issue: āĻā§ā§āĻāĻāĻŋ medication regimen standard recommendations āĻĨā§āĻā§ āĻāĻŋāύā§āύ; dose āĻāĻŦāĻ indication āϝāĻžāĻāĻžāĻ āĻ āĻĒāϰāĻŋāĻšāĻžāϰā§āϝāĨ¤
Overall assessment confidence: 0.70
16.3 Actionable Plan / āĻāϰāĻŖā§ā§
- Within the next clinical review: Dermatologist āĻĻāĻŋā§ā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ skin āĻ nail examination āĻāϰāĻžāϤ⧠āĻšāĻŦā§āĨ¤
- Before continuing questionable regimens: Cefixime, Ivermectin āĻ Permethrin-āĻāϰ dose/schedule āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
- Before systemic antifungal treatment: Nail fungal confirmation āĻāĻŦāĻ baseline LFT āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
- During follow-up: āύāϤā§āύ burrows, rash, fever, pus, spreading redness, jaundice āĻŦāĻž significant adverse effects āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
- Household management: Scabies clinically supported āĻšāϞ⧠close contacts āĻ bedding/clothing management āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Action-plan confidence: 0.98
đĻ SECTION 17 â References â Textbooks, Guidelines & Peer-Reviewed Journals / āϤāĻĨā§āϝāϏā§āϤā§āϰ
A. Standard Medical Textbooks / āĻĒā§āϰāĻžāĻŽāĻžāĻŖā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāĻā§āĻāĻžāύ āĻŦāĻ
- Andrews’ Diseases of the Skin: Clinical Dermatology. 14th edition. Elsevier. Relevant topics: Parasitic infestations, superficial fungal infections and inflammatory dermatosesāĨ¤
- Davidson’s Principles and Practice of Medicine. 24th edition. Elsevier. Dermatology section: Common skin infections and infestationsāĨ¤
- Harrison’s Principles of Internal Medicine. 22nd edition. McGraw Hill. Relevant topics: Ectoparasitic infestation and dermatophyte infectionsāĨ¤
- Katzung’s Basic & Clinical Pharmacology. 16th edition. McGraw Hill. Relevant topics: Antimicrobial, antiparasitic, antihistamine and corticosteroid pharmacologyāĨ¤
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th edition. McGraw Hill. Relevant topics: Antifungal and antiparasitic medicationsāĨ¤
āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ edition-āĻāϰ page number āϏāϰāĻžāϏāϰāĻŋ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšā§āύāĻŋ; āϤāĻžāĻ āĻ āύā§āĻŽāĻžāύ āĻāϰ⧠page number āĻĻā§āĻā§āĻž āĻšā§āύāĻŋāĨ¤
B. Clinical Guidelines / āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻĻā§āĻļāĻŋāĻāĻž
1. CDC â Clinical Care of Scabies (2023).
Permethrin āĻāĻŦāĻ Ivermectin-āĻāϰ recommended use, dosage and repeat-treatment scheduleāĨ¤
2. CDC â Preventing Scabies (2023).
Household contact treatment, washing and environmental measuresāĨ¤
3. Nenoff P, et al. S1 Guideline on Onychomycosis (2023).
Fungal confirmation, systemic treatment āĻāĻŦāĻ antifungal-associated liver monitoringāĨ¤
C. Peer-Reviewed Journals with DOI / DOI-āϏāĻš āĻāĻŦā§āώāĻŖāĻžāĻĒāϤā§āϰ
1. Uzun S, et al. Clinical practice guidelines for the diagnosis and treatment of scabies. International Journal of Dermatology. 2024;63(12):1642â1656.
DOI: 10.1111/ijd.17327
2. Nenoff P, et al. S1 Guideline onychomycosis. Journal der Deutschen Dermatologischen Gesellschaft. 2023.
DOI: 10.1111/ddg.14988
D. Bangladesh Drug Database / āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§āϰ āĻāώā§āϧā§āϰ āϤāĻĨā§āϝāϏā§āϤā§āϰ
MedEx Bangladesh: Cefim-3 DS, Atrizin, Alice, Solupred, Combiderm combination, Clarizol, Fungiben āĻāĻŦāĻ Perosa-āĻāϰ generic, composition, therapeutic class, dosage āĻ listed price āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤ Cosmetic products-āĻāϰ āĻā§āώā§āϤā§āϰ⧠MedEx listing āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋ; āϏā§āĻā§āϞā§āϰ āϤāĻĨā§āϝ āĻĒā§āĻĨāĻ product sources āĻĨā§āĻā§ āύā§āĻā§āĻž āĻšā§ā§āĻā§āĨ¤
Drug-information confidence: 0.96
Final Clinical Working Diagnosis / āĻā§ā§āĻžāύā§āϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Suspected Scabies with Possible Onychomycosis and Associated Pruritic Dermatitis.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϏāĻĒāĻžāĻāĻā§āĻž, āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻ āĻā§āϞāĻāĻžāύāĻŋāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
Diagnostic status: Provisional â not confirmed.
Overall confidence score: 0.70/1.00
Author: Md. Rafiqul Islam Lipu
Publication Series: LIPU MED
Website: Raiyyantahsan.com
Date: Wednesday, 21 October 2026
Time: 12:36 PM (Bangladesh Standard Time, UTC+06:00)